← Home / Foghorn Therapeutics Inc. (FHTX)
Stock Analysis

Foghorn Therapeutics Inc. (FHTX)

FHTX
FHTX · Healthcare • Biotechnology
6.68 -2.12%
Track FHTX in your personal workspace Monitor performance, SPY relative strength and WOI View from your watchlist.
Alert me when FHTX price is:
52W Range Position
89%
LOWMIDHIGH
Trend
Constructive
Momentum
Neutral
Updated: 2026-08-26 23:22 UTC
WOI Investment Thesis
Constructive
Watch confirmation and structural levels before acting.
⚖️
✓
Fundamentals
Strong / Negative / Pressured / Strong
✓
Price Structure
Constructive
•
Momentum
Neutral
×
Current Resistance
Below Resistance
Risk Level
Moderate
Analysis Scope
1Y Daily
Key Decision Levels
✓
Hold Above
No reliable structural support level is currently available.
Not available
↗
Break Above
No setup-specific trigger is available; nearest structural resistance is shown.
6.95
🎯
Next Objective
No defined objective is currently available for the primary technical setup.
Not available
×
Thesis Break
No setup-specific invalidation level is currently defined.
Not available
Recent Company Events
SEC VERIFIED
Latest material filings
AUG
6
●
Financial Results
HIGH
FHTX reports financial results
On August 6, 2026 , Foghorn Therapeutics Inc.
8-K Filing • SEC EDGAR
MAY
7
●
Financial Results
HIGH
Foghorn Therapeutics Provides First Quarter 2026 Financial and Corporate Update
- FHD-909 (LY4050784) Phase 1 dose-escalation trial on track; preclinical combination data with anti-PD-1 antibody demonstrates potential for robust and durable regression with anti-tumor immune memory - Selective CBP degrader FHT-171 advancing for the treatment of ER+ breast cancer with IND anticipated in 2027 -Sel...
8-K Filing • SEC EDGAR
What's Driving FHTX?
• No active technical setup
Momentum is Neutral. No qualified technical setup is currently active.
◆ Business quality is mixed
Revenue growth is strong. Profitability is negative. Cash generation is pressured. Balance-sheet quality is strong.
Full Analysis Workspace
Technical Signal
No Active Technical Setup
•
No qualified technical setup is currently active.
RSI(14)
62.1
Price Chart
FHTX — 1D Chart
Open Full Workspace
Valuation Snapshot (TTM)
Full valuation · Ratios use trailing twelve months
Updated 2026-08-25
Cash
Cash-flow pressure
TTM free cash flow is negative. P/FCF and FCF yield should be read with caution.
Market Cap
$408.0M
Company size
EV
$283.5M
Debt-adjusted value
P/S
11.1
Premium
P/B
-4.9
Not meaningful
EV/Sales
7.7
Balanced
EV/EBIT
-14.1
Not meaningful
P/FCF
-7.9
Not meaningful
FCF Yield
-12.73%
Cash return
Not financial advice
Business Lens
Financial context is mixed
Financial conditions require selective monitoring.
↗
Revenue Growth
Strong
●
Profitability
Negative
≈
Cash Flow
Pressured
⚖
Balance Sheet
Strong
💵 Revenue
16.07M
↗ Strong
📈 Net Income
-7.19M
↘ Negative
🧮 EPS (Basic)
-0.10
↘ Negative
Foghorn Therapeutics Inc.
Healthcare • Biotechnology
You Might Also Like